Intermediate endpoint biomarkers for lung cancer chemoprevention

Calum E. MacAulay; Stephen Lam; Helga Klein-Parker; Adi Gazdar; Martial Guillaud; Peter W. Payne; Jean C. Le Riche; Chris Dawe; Pierre Band; Branko Palcic

doi:10.1117/12.307094

29 April 1998 Intermediate endpoint biomarkers for lung cancer chemoprevention

Calum E. MacAulay, Stephen Lam, Helga Klein-Parker, Adi Gazdar, Martial Guillaud, Peter W. Payne, Jean C. Le Riche, Chris Dawe, Pierre Band, Branko Palcic

Author Affiliations +

Proceedings Volume 3260, Optical Investigations of Cells In Vitro and In Vivo; (1998) https://doi.org/10.1117/12.307094
Event: BiOS '98 International Biomedical Optics Symposium, 1998, San Jose, CA, United States

Abstract

Given the demographics of current and ex-smoking populations in North America, lung cancer will be a major problem in the foreseeable future. Early detection and treatment of lung cancer holds great promise for the management of this disease. Unlike cervical cancer, the physical, complete removal/destruction of all dysplastic lesions in the bronchial tree is not possible; however, treatment of the lesions using a chemopreventive agent is. Intermediate biomarkers have been used to screen promising chemopreventive agents for larger population studies. We have examined the natural history of lung cancer development by following a group of subjects at high risk of developing lung cancer using fluorescence endoscopy to identify the areas of abnormality for biopsy. Approximately 900 biopsies have been collected in this fashion and graded by at least two experienced, expert pathologists. Using an interactive version of the Cyto-Savant (Oncometrics Imaging Corp.), cytometric and tissue architectural data were collected from these biopsies. Using only the data from the normal and invasive cancer biopsies, quantitative morphometric and architectural indices were generated and calculated for all the collected biopsies. These indices were compared with Loss of Heterozygosity (LOH) of ten sites commonly associated with cancer. These results and the application of these quantitative measures to two small chemoprevention studies will be reported.

Citation Download Citation

Calum E. MacAulay, Stephen Lam, Helga Klein-Parker, Adi Gazdar, Martial Guillaud, Peter W. Payne, Jean C. Le Riche, Chris Dawe, Pierre Band, and Branko Palcic "Intermediate endpoint biomarkers for lung cancer chemoprevention", Proc. SPIE 3260, Optical Investigations of Cells In Vitro and In Vivo, (29 April 1998); https://doi.org/10.1117/12.307094

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available